Alza, U. S. Bioscience Inc. sales and marketing update

The companies agreed to form a 60-person U.S. sales force to market UBS's Hexalen (altretamine), to treat ovarian cancer, and NeuTrexin (trimetrexate glucuronate), for moderate-to-severe Pneumocystis carinii pneumonia (PCP). UBS will contribute 15 sales reps while AZA will contribute 45 reps. Co-promotion is scheduled to begin July 1. ...